Wedbush lowered the firm’s price target on Aprea Therapeutics (APRE) to $7 from $11 and keeps an Outperform rating on the shares. The firm notes the company announced preliminary proof-of-concept data for WEE1 inhibitor APR-1051. Wedbush believes the recent partial response is further validating of the clinical potential for APR-1051, and the firm expects to continue to see dose responses as higher dosing cohorts are enrolled.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APRE:
- Aprea Therapeutics appoints Kennedy as Chief Medical Advisor
- Aprea Therapeutics Announces Financing and Early Trial Response
- Aprea Therapeutics price target lowered to $4 from $5 at H.C. Wainwright
- Aprea Therapeutics prices 6.29M shares at 89c in private placement
- Aprea Therapeutics announces early PoC data in ACESOT-1051 trial